Trial Profile

Phase 1/2, Open-Label Clinical Study to Evaluate the Safety and Efficacy of Intrathecal TSHA-101 Gene Therapy for Treatment of Infantile Onset GM2 Gangliosidosis

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 21 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TSHA 101 (Primary)
Indications GM2 gangliosidoses
Focus Adverse reactions; First in man

Most Recent Events

15 Feb 2024 According to a Taysha Gene Therapies media release, The Company transferred rights back to Queen's University (Queen's) for TSHA-101 in GM2 gangliosidosis, resulting in Queen's regaining exclusive IP to the program.
08 May 2023 Planned primary completion date changed from 12 Mar 2023 to 12 Mar 2027.
12 Sep 2022 Status changed from suspended to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com